Jain R, Krishnan S, Lee S, Amoozgar Z, Subudhi S, Kumar A, Posada J, Lindeman N, Lei P, Duquette M, Roberge S, Huang P, Andersson P, Datta M, Munn L, Fukumura D
Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma.
Res Sq. 2023;:ePub - PMID: 38234841 - PMCID: PMC10793505 - DOI: 10.21203/rs.3.rs-3707472/v1
Iorgulescu JB, Ruthen N, Ahn R, Panagioti E, Gokhale PC, Neagu M, Speranza MC, Eschle BK, Soroko KM, Piranlioglu R, Datta M, Krishnan S, Yates KB, Baker GJ, Jain RK, Suvà ML, Neuberg D, White FM, Chiocca EA, Freeman GJ, Sharpe AH, Wu CJ, Reardon DA
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
Front Immunol. 2023;14:1297932 - PMID: 38213329 - PMCID: PMC10782385 - DOI: 10.3389/fimmu.2023.1297932
Abbott KL, Ali A, Reinfeld BI, Deik A, Subudhi S, Landis MD, Hongo RA, Young KL, Kunchok T, Nabel CS, Crowder KD, Kent JR, Madariaga MLL, Jain RK, Beckermann KE, Lewis CA, Clish CB, Muir A, Rathmell WK, Rathmell JC, Heiden MGV
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.
bioRxiv. 2023;:ePub - PMID: 38187626 - PMCID: PMC10769456 - DOI: 10.1101/2023.12.24.573250
Harkos C, Stylianopoulos T, Jain RK
Mathematical modeling of intratumoral immunotherapy yields strategies to improve the treatment outcomes.
PLoS Comput Biol. 2023;19(12):e1011740 - PMID: 38113269 - PMCID: PMC10763956 - DOI: 10.1371/journal.pcbi.1011740
Wolf B, Weydandt L, Dornhöfer N, Hiller GGR, Höhn AK, Nel I, Jain RK, Horn LC, Aktas B
Desmoplasia in cervical cancer is associated with a more aggressive tumor phenotype.
Sci Rep. 2023;13(1):18946 - PMID: 37919378 - PMCID: PMC10622496 - DOI: 10.1038/s41598-023-46340-4
Nikmaneshi MR, Jain RK, Munn LL
Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.
PLoS Comput Biol. 2023;19(6):e1011131 - PMID: 37289729 - PMCID: PMC10249820 - DOI: 10.1371/journal.pcbi.1011131
Plotkin SR, Allen J, Dhall G, Campian JL, Clapp DW, Fisher MJ, Jain RK, Tonsgard J, Ullrich NJ, Thomas C, Edwards LJ, Korf B, Packer R, Karajannis MA, Blakeley JO
Multicenter, prospective, phase 2 study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
Neuro Oncol. 2023;25(8):1498-1506 - PMID: 37010875 - PMCID: PMC10398799 - DOI: 10.1093/neuonc/noad066
Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, Duquette M, Fukumura D, Jain RK
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
J Immunother Cancer. 2023;11(3):ePub - PMID: 36898734 - PMCID: PMC10008211 - DOI: 10.1136/jitc-2022-005583
Gupta N, Ochiai H, Hoshino Y, Klein S, Zustin J, Ramjiawan RR, Kitahara S, Maimon N, Bazou D, Chiang S, Li S, Schanne DH, Jain RK, Munn LL, Huang P, Kozin SV, Duda DG
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models.
Cancers (Basel). 2023;15(4):ePub - PMID: 36831366 - PMCID: PMC9954510 - DOI: 10.3390/cancers15041021
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin S, Matsui A, Pu Z, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Bardeesy N, Ho WJ, Jain RK, Duda DG
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
bioRxiv. 2023;:ePub - PMID: 36747853 - PMCID: PMC9901023 - DOI: 10.1101/2023.01.26.525680
Boucher Y, Posada JM, Subudhi S, Kumar AS, Rosario SR, Gu L, Kumra H, Mino-Kenudson M, Talele NP, Duda DG, Fukumura D, Wo JY, Clark JW, Ryan DP, Fernandez-Del Castillo C, Hong TS, Pittet MJ, Jain RK
Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.
Clin Cancer Res. 2023;29(8):1605-1619 - PMID: 36749873 - PMCID: PMC10106451 - DOI: 10.1158/1078-0432.CCR-22-1630
Datta M, Chatterjee S, Perez EM, Gritsch S, Roberge S, Duquette M, Chen IX, Naxerova K, Kumar AS, Ghosh M, Emblem KE, Ng MR, Ho WW, Kumar P, Krishnan S, Dong X, Speranza MC, Neagu MR, Iorgulescu JB, Huang RY, Youssef G, Reardon DA, Sharpe AH, Freeman GJ, Suvà ML, Xu L, Jain RK
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Proc Natl Acad Sci U S A. 2023;120(6):e2219199120 - PMID: 36724255 - PMCID: PMC9963691 - DOI: 10.1073/pnas.2219199120
Voutouri C, Hardin CC, Naranbhai V, Nikmaneshi MR, Khandekar MJ, Gainor JF, Stylianopoulos T, Munn LL, Jain RK
Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2.
Proc Natl Acad Sci U S A. 2023;120(3):e2211132120 - PMID: 36623200 - PMCID: PMC9934028 - DOI: 10.1073/pnas.2211132120
Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
Clin Cancer Res. 2023;29(1):30-39 - PMID: 35969170 - PMCID: PMC10274152 - DOI: 10.1158/1078-0432.CCR-22-1366
14